版本:
中国

BRIEF-Pulmatrix to pay Respivert up-front, non-refundable license fee of $1 mln

June 13 Pulmatrix Inc-

* Pulmatrix - will pay Respivert up-front, non-refundable license fee of $1 million in partial consideration for rights granted by respivert to company - sec filing

* Pulmatrix - following commencement of commercial sales of licensed products, co will pay respivert designated amounts when certain milestone events occur

* Pulmatrix Inc - development milestones and commercial milestones range from $1 million to $80 million

* Pulmatrix Inc - co required to pay respivert royalties on all sales of licensed products, with such royalties ranging from 6% - 10% of sales Source text: (bit.ly/2swuyjg) Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐